The group of AGC protein kinases includes more than 60 protein kinases in the human genome,
classified into 14 families: PDK1, AKT/PKB, SGK, PKA, PKG, PKC, PKN/PRK, RSK, NDR…

PURPOSE: Agonistic analogs of luteinizing hormone-releasing hormone (LHRH) are widely
used for therapy of advanced prostate cancer based upon their ability to suppress …

GHRH is produced in a variety of extrahypothalamic tissues, including some neoplasms. We
have previously reported that GHRH antagonists can inhibit the growth of various human …

The PIF-pocket of AGC protein kinases participates in the physiologic mechanism of
regulation by acting as a docking site for substrates and as a switch for the transduction of the …

iRGD is a derivative of the integrin-binding peptide RGD, which selectively increases the
penetrability of tumor tissue to various coadministered substances in several preclinical models…

We used a pharmacophore hybridization strategy to combine key structural elements of
merbarone and etoposide and generated new type II topoisomerase (topoII) poisons. This first …

Drugs targeting human topoisomerase II (topoII) are used in clinical practice since decades.
Nevertheless, there is an urgent need for new and safer topoII inhibitors due to the …

We disclose a novel class of 6-amino-tetrahydroquinazoline derivatives that inhibit human
topoisomerase II (topoII), a validated target of anticancer drugs. In contrast to topoII-targeted …

Prostate cancer is one of the most frequent malignancies in the Western world. The identification
of additional molecular markers is needed to refine the diagnosis of prostate cancer …

We previously reported a first set of hybrid topoisomerase II (topoII) poisons whose chemical
core merges key pharmacophoric elements of etoposide and merbarone, which are two well…